Aspen Neuroscience, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aspen Neuroscience, Inc. - overview
Established
2018
Location
San Diego, California, US
Primary Industry
Biotechnology
About
Aspen Neuroscience, Inc. , based in the US, specializes in innovative cell therapy solutions aimed at treating neurological conditions, particularly Parkinson's disease. Founded in 2018 and headquartered in San Diego, California, Aspen Neuroscience develops advanced therapies utilizing autologous induced pluripotent stem cells (iPSCs). The firm has attracted attention for its product ANPD001, targeting the restoration of dopamine neurons in Parkinson’s patients.
In October 2026, Aspen Neuroscience, Inc. raised approximately USD 140. 63 million in an IPO, selling around 9. 4 million shares at USD 15 per share on Nasdaq, under the ticker "ASPE".
Aspen Neuroscience specializes in personalized cell therapy, offering the world's first autologous iPSC-derived neuron replacement therapy designed for Parkinson's disease. The therapy, ANPD001, addresses the severe loss of dopamine neurons in affected patients, which can exceed 50% before diagnosis. It involves reprogramming a small sample of the patient's skin cells into unique iPSCs, with the aim of restoring neuronal function and enhancing patient quality of life. Currently, ANPD001 is undergoing the Phase 1/2a ASPIRO clinical trial to assess its effectiveness within the U.
S. market, targeting individuals with Parkinson's and collaborating healthcare institutions. Aspen Neuroscience is in the investigational stage with ANPD001, which is not yet approved for commercial sale. Therefore, the company does not generate revenue from direct sales.
Its business model relies on investments and partnerships within clinical trials, focusing on research and development costs. Future revenue will depend on the successful commercialization of ANPD001 following FDA approval, at which point the company will establish pricing strategies for healthcare facilities and potential pharmaceutical distributors.
Current Investors
ARCH Venture Partners, Domain Associates, Frazier Healthcare Partners, OrbiMed Advisors, Alexandria Venture Investments, SG Growth Capital, GV, Kite Pharma, Inc., Mirae Asset Capital, California Institute for Regenerative Medicine, Cormorant Asset Management, Revelation Partners, LYFE Capital, Gaingels , Section 32, LifeForce Capital, BNY Investments Newton, BAM Elevate, Medical Excellence Capital, Axon Ventures, Timefolio Capital, Prebys Foundation
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.aspenneuroscience.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aspen Neuroscience, Inc. - financials
| Fiscal Year Ended | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
Aspen Neuroscience, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Aspen Neuroscience, Inc. | - | ||||||||
| Series C | Completed | Aspen Neuroscience, Inc. | - | ||||||||
| Venture Debt | Completed | Aspen Neuroscience, Inc. | - | ||||||||
| Series B | Completed | Aspen Neuroscience, Inc. | - | ||||||||
| Series A | Completed | Aspen Neuroscience, Inc. | - |
Displaying 1 - 5 of 7
Aspen Neuroscience, Inc. - employee data


Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.